Abstract
Paclitaxel and carboplatin is widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC); however, median survival remains < 1 year. One strategy to improve survival is to add a third active drug with a differing mechanism of action. Gemcitabine is a novel antimetabolite with considerable activity in NSCLC. The primary objective of this Phase I/II study was to determine the maximally tolerated dose of gemcitabine administered with fixed doses of paclitaxel and carboplatin in untreated patients with advanced NSCLC.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenocarcinoma / drug therapy
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carboplatin / administration & dosage
-
Carboplatin / adverse effects
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / adverse effects
-
Deoxycytidine / analogs & derivatives
-
Dose-Response Relationship, Drug
-
Female
-
Gemcitabine
-
Humans
-
Lung Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Neutropenia / chemically induced
-
Paclitaxel / administration & dosage
-
Paclitaxel / adverse effects
-
Thrombocytopenia / chemically induced
Substances
-
Deoxycytidine
-
Carboplatin
-
Paclitaxel
-
Gemcitabine